How much does spirometry actually improve detection rates?
The evidence is clear: spirometry screening catches a large number of COPD cases that would otherwise go undiagnosed. In the SUMMIT lung cancer screening study of over 16,000 current or former smokers aged 55-77, nearly one in five (19.7%) met criteria for undiagnosed COPD when spirometry was added to their health check [3]. Similarly, the Yorkshire Lung Screening Trial found that 17% of attendees had undiagnosed airflow obstruction with respiratory symptoms, representing potentially undiagnosed COPD [8]. In a general population study of nearly 30,000 adults, researchers calculated that for every 10 smokers with respiratory symptoms who undergo spirometry, one new case of COPD will be detected [2]. These figures show that spirometry is not just a minor improvement—it is a powerful tool for uncovering a hidden epidemic.
The impact is even more striking when you consider how many COPD cases are currently missed. In the Canadian CanCOLD study, 84% of people with mild (GOLD stage 1) COPD and 58% of those with moderate or worse COPD had never been diagnosed before spirometry screening [6]. This means that without screening, the vast majority of early-stage COPD goes completely unrecognized.
Is simplified spirometry a practical alternative for large-scale screening?
Traditional spirometry requires multiple maneuvers and strict quality control, which can take over 30 minutes and limit its use in busy community settings. However, a major 2025 community-based study of 619 participants in China found that a simplified version—using just the first acceptable maneuver—was nearly as accurate as the full protocol. The simplified test had a sensitivity of 96.6% (meaning it correctly identified 96.6% of people with COPD) and a specificity of 86.0% (correctly ruling out 86% of those without the disease) [1][5]. Crucially, the average examination time dropped from 32 minutes to under 3 minutes—a 29-minute saving that makes large-scale screening far more feasible [1][5]. This suggests that the main barrier to spirometry screening (time and complexity) can be overcome without sacrificing much accuracy.
Another practical approach is combining spirometry with existing healthcare visits. A 2023 study integrated handheld microspirometry into the pre-ablation workup for atrial fibrillation patients. Of 232 patients screened, 20.3% showed airflow limitation, and 7.3% ultimately received a new diagnosis of chronic respiratory disease (COPD or asthma) [4]. This shows that embedding spirometry into routine care for high-risk groups can efficiently boost detection rates.
Who benefits most from spirometry screening, and what are the limitations?
The evidence consistently shows that the biggest gains come from screening high-risk populations—particularly older smokers or former smokers with respiratory symptoms. In the SUMMIT study, undiagnosed COPD was more common in current smokers (54.9% of undiagnosed cases were current smokers) and in people from ethnic minority groups [3]. The Yorkshire trial found that those with undiagnosed COPD were more likely to be male and current smokers, though they had milder disease and fewer symptoms than those already diagnosed [7][8]. This means screening catches people at an earlier, more treatable stage—a key goal of any screening program.
However, screening is not perfect. A 2022 study comparing six COPD screening questionnaires found that even the best questionnaire (the Lung Function Questionnaire) had an area under the curve (AUC) of 0.785, meaning it was only moderately accurate at distinguishing who has COPD from who does not [9]. Spirometry itself is more accurate, but it still has limitations: in the Yorkshire trial, 19% of people with a GP diagnosis of COPD did not actually have airflow obstruction on spirometry, suggesting potential misdiagnosis [7][8]. Also, not everyone with abnormal spirometry results will accept a referral—in the atrial fibrillation study, only 62% of those with airflow limitation opted to see a pulmonologist, often because they felt their symptoms were mild [4]. So while spirometry screening clearly improves detection, its real-world impact depends on patient engagement and follow-up.
About These Sources
This answer is built on 9 peer-reviewed studies — published from 2021 to 2025, 2 from 2024 or later, 7 in Q1 journals, collectively cited 112 times — selected as the most relevant from 12 studies that passed quality screening, drawn from 65 papers retrieved from a database of over 500 million.
Sources used in this answer
Community-Based COPD Screening Using Simplified Spirometry
In a community-based study of 619 participants, simplified spirometry (using just one acceptable maneuver) had 96.6% sensitivity and 86.0% specificity for detecting COPD, and took only 2.8 minutes on average versus 32.1 minutes for routine spirometry [1].
Potential clinical implications of targeted spirometry for detection of COPD: A contemporary population-based cohort study
In a general population cohort of 29,678 adults, targeted spirometry in smokers with respiratory symptoms detected one new COPD case for every 10 people screened; 73% of those with undiagnosed COPD had at least two other treatable conditions [2].
Detection of COPD in the SUMMIT Study lung cancer screening cohort using symptoms and spirometry
In the SUMMIT lung cancer screening study of 16,010 current/former smokers, 19.7% had undiagnosed COPD detected by spirometry; undiagnosed individuals were more likely to be male, current smokers, and from ethnic minority groups [3].
Implementation of a screening and management pathway for chronic obstructive pulmonary disease in patients with atrial fibrillation
In 232 atrial fibrillation patients screened with handheld microspirometry, 20.3% showed airflow limitation, and 7.3% received a new diagnosis of chronic respiratory disease after referral [5].
Discriminative Accuracy of Simplified Spirometry for Identifying Spirometry-Defined COPD in the Community.
In the same community-based study as paper [1], prebronchodilator simplified spirometry had a positive predictive value of 77.4% and a negative predictive value of 98.1% for identifying COPD [6].
Impaired Spirometry and COPD Increase the Risk of Cardiovascular Disease
In the CanCOLD study of 1,561 participants, 84% of GOLD stage 1 COPD and 58% of GOLD stage ≥2 COPD were undiagnosed; impaired spirometry was associated with a doubled risk of developing cardiovascular disease over 6.3 years [7].
Spirometry and under-diagnosis of COPD in a lung cancer screening cohort
In the Yorkshire Lung Screening Trial of 3,920 attendees, 44% had airflow obstruction on spirometry; 59% of those with obstruction had no prior COPD diagnosis, and 19% of those with a COPD code had no obstruction on spirometry [9].
Measuring spirometry in a lung cancer screening cohort highlights possible underdiagnosis and misdiagnosis of COPD
In the same Yorkshire trial, 17% of attendees had undiagnosed airflow obstruction with symptoms; those with undiagnosed COPD had milder disease and were more likely to be current smokers than those already diagnosed [10].
Accuracy of Six Chronic Obstructive Pulmonary Disease Screening Questionnaires in the Chinese Population
Among 909 Chinese patients, six COPD screening questionnaires had AUCs ranging from 0.667 to 0.785, with the Lung Function Questionnaire performing best; none were as accurate as spirometry [12].